MDMA

PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

Retrieved on: 
Friday, March 8, 2024

The Company is pleased to announce the voting results from its annual general and special meeting of the shareholders of the Company (“Shareholders”) held on Tuesday, February 27, 2024 (the “Meeting”).

Key Points: 
  • The Company is pleased to announce the voting results from its annual general and special meeting of the shareholders of the Company (“Shareholders”) held on Tuesday, February 27, 2024 (the “Meeting”).
  • Shareholders voted in favour of each resolution put forth at the Meeting.
  • “PharmAla continues to make the important choices necessary for the future of both our business, and the Psychedelic Pharmaceuticals sector more broadly,” said Jodi Butts, Board Chair, PharmAla Biotech.
  • “We are grateful that PharmAla’s shareholders have agreed with management’s recommendations on a variety of timely corporate governance matters.

MAPS Announces Celestial Plans for Its 38th Anniversary

Retrieved on: 
Thursday, March 7, 2024

The event will also feature a Psychedelic Speakers Series curated by MAPS and a camping area for MAPS supporters.

Key Points: 
  • The event will also feature a Psychedelic Speakers Series curated by MAPS and a camping area for MAPS supporters.
  • SAN JOSE, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- MAPS (Multidisciplinary Association for Psychedelic Studies) is excited to announce its collaboration with Texas Eclipse 2024 for its 38th anniversary celebration.
  • MAPS’ 38th anniversary, celebrating its founding on April 8, 1984, coincides with the last total solar eclipse that will be visible in the contiguous US for another 20 years.
  • The collaboration with Texas Eclipse will feature MAPS’ 38th Anniversary Psychedelic Speaker Series with MAPS Founder and President Rick Doblin, Ph.D., Allyson Grey & Alex Grey, Sutton King, Paul Stamets, and more!

Beckley Waves Celebrates a Year of Milestones, Including $3.3 Million in New Funding, 200 Retreat Participants, the Inaugural Cohort of Therapist Training, and the Acquisition of Ketamine Therapy Provider Nue Life

Retrieved on: 
Tuesday, March 5, 2024

Through its portfolio of operating companies, Beckley Waves has also expanded programs for practitioner training and psilocybin retreats, accelerating the company’s growth.

Key Points: 
  • Through its portfolio of operating companies, Beckley Waves has also expanded programs for practitioner training and psilocybin retreats, accelerating the company’s growth.
  • In September, the company also acquired at-home ketamine therapy provider Nue Life and will continue Nue Life’s work to provide safe and scalable access to ketamine-assisted therapy in underserved areas across multiple US states.
  • In 2024, Beckley Retreats will offer dedicated retreats in Jamaica and the Netherlands that will be exclusively for women, veterans, and the BIPOC community.
  • "With our ongoing momentum, we will keep the flywheel spinning and continue to allow the Beckley Waves Ecosystem to play a catalytic role in our shared path to widespread access."

Optimi Announces Closing of First Tranche of Non-Brokered Private Placement

Retrieved on: 
Wednesday, February 28, 2024

The Company intends to use the net proceeds from the Offering to obtain its Drug Establishment License, facilitate commercialization, and for general working capital.

Key Points: 
  • The Company intends to use the net proceeds from the Offering to obtain its Drug Establishment License, facilitate commercialization, and for general working capital.
  • JJ Wilson and Dane Stevens, co-founders of Optimi, emphasize, “We are fully dedicated to Optimi's mission of becoming the leading end-to-end supplier of GMP psychedelics.
  • In addition to the financing, the Company also announces that specific founders have agreed to a one-year voluntary lock-up period for their founder shares.
  • This additional commitment, along with the founders' participation in the financing, emphasizes their dedication to commercializing the business and establishing sustainable markets for its products.

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

Retrieved on: 
Tuesday, February 27, 2024

Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted three additional patent applications under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

Key Points: 
  • The patent applications refer to novel proprietary compositions of 3,4-Methylenedioxymethamphetamine (MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™.
  • These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (“USPTO”).
  • In addition, seven patent applications were filed under the international PCT.
  • Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer, stated, “These latest patent applications are expected to significantly expand our IP protection, and further enhance our leadership in the psychedelic space.

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Retrieved on: 
Tuesday, February 27, 2024

The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.

Key Points: 
  • The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.
  • These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (“USPTO”).
  • As part of this collaboration, eight other applications have been filed by Clearmind with the USPTO for various combinations, three of which are for the combination of PEA with Clearmind’s 5-methoxy-2-aminoindane compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.
  • In addition, seven applications were filed under the PCT.

Beckley Academy Publishes First Open-Source Learning Framework to Advance Psychedelic-Assisted Therapy Training Standards

Retrieved on: 
Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Beckley Academy , the learning studio that prepares and trains practitioners to provide psychedelic-assisted therapy (PAT) with Ketamine, Psilocybin, and MDMA, announced today the open-source publication of its research: A Psychedelic-Assisted Therapy Learning Framework .

Key Points: 
  • NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Beckley Academy , the learning studio that prepares and trains practitioners to provide psychedelic-assisted therapy (PAT) with Ketamine, Psilocybin, and MDMA, announced today the open-source publication of its research: A Psychedelic-Assisted Therapy Learning Framework .
  • This industry-first learning framework will serve as a much-needed foundation to advance national training standards for clinicians to provide ethical and effective psychedelic-assisted therapy.
  • Currently, no national training standards or certifications exist for psychedelic practitioners, though many organizations have independently created training programs, practice guidelines, and codes of ethics.
  • Beckley Academy co-founding team members Deborah Gardner and Shirelle Noble recognized the opportunity to analyze existing publications and create a unified framework.

PharmAla named an Intellectual Property Ontario Client

Retrieved on: 
Thursday, February 22, 2024

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) announces today that it has been accepted as a client of Intellectual Property Ontario (IPON).

Key Points: 
  • VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) announces today that it has been accepted as a client of Intellectual Property Ontario (IPON).
  • PharmAla is further pleased to note that IPON has approved its initial Scope of Work pertaining to the national phase entry into numerous markets of the PharmAla ALA and ABA molecule families and will provide a non-dilutive grant of approximately $35,000 to PharmAla to complete this work.
  • “We are pleased to be recognized as a worthy recipient of this grant funding from the Province of Ontario and IPON,” said Dr. Harpreet Kaur, VP of Research at PharmAla Biotech.
  • “As our drug discovery program continues to bear fruit, locking in valuable intellectual property remains a crucial and integral part of PharmAla’s long-term drug discovery program.

PharmAla Data to be Published in ACS Chemical Neuroscience

Retrieved on: 
Tuesday, February 20, 2024

It focuses on identifying key targets that are crucial for optimizing the safety and effectiveness of these compounds.

Key Points: 
  • It focuses on identifying key targets that are crucial for optimizing the safety and effectiveness of these compounds.
  • “PharmAla’s drug development program represents some of the world’s best work in the development of novel entactogenic molecules.
  • This research opens new avenues for developing innovative treatments in mental health care,” said Dr. Harpreet Kaur, VP of Research at PharmAla Biotech.
  • “Publication of our PCT filing for the P1 molecule should provide more context and information for potential drug development partners,” said Nick Kadysh, CEO, PharmAla Biotech.

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Retrieved on: 
Friday, February 23, 2024

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount.
  • The patents and applications being sold disclose and claim the synergistic combination of cannabidiol and second therapeutic agents for the treatment of cancer.
  • The divested portfolio includes patents issued in the U.S., Australia, Canada, China, Europe, and Japan, with patent applications pending in Canada, Israel, and Korea.
  • Enveric retains no ownership rights in the divested portfolio, any companies owned by, or to be formed by the recipients.